Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals (XENE) will present Phase 3 data for azetukalner, a KV7 channel opener, at the 16th European Epilepsy Congress. The company plans six presentations, including topline X-TOLE2 study results for focal onset seizures and mechanistic characterization of azetukalner's potential additive effects with other antiseizure medications. Xenon aims to highlight azetukalner's differentiated attributes and its potential to enhance seizure control through rational polytherapy.

Xenon Pharmaceuticals (XENE) reported Q2 2026 results and discussed clinical progress. Cash was $1,245.1M as of June 30, 2026, expected to fund operations into 2029. Q2 net loss was $110.7M ($1.11/share). Management said Azetukalner NDA submission for focal onset seizures is on track for Q3 2026, with Phase 3 programs in major and bipolar depression and pain pipeline updates.

Xenon Pharmaceuticals reported Q2 revenue changes by region, with Americas up 6% and EMEA up 15% excluding non-recurring license and royalty revenue, while Asia-Pacific fell 19% versus a prior-year China pull-forward. Q2 gross margin rose to 74%. Operating expenses were $132.1M. Cash totaled $552M. Full-year 2026 revenue outlook raised to $610M-$630M.

Xenon Pharmaceuticals Inc. (XENE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Xenon Reports Q2 2026 Financial Results and Provides Business Update • NDA submission for azetukalner on track for Q3 2026 following pre-NDA meeting with FDA • Phase 3 X-TOLE3 study in FOS and X-ACKT study in PGTCS continue to enroll • Three Phase 3 studies of azetuk

Meridian Hedged Equity Fund highlighted ACV Auctions (ACVA) in its Q2 2026 investor letter, noting its record Q1 results, $100M share repurchase plan, and AI-driven solutions. ACVA's stock declined 10.19% over the past month and 43.27% over the past year, with a market cap of $1.14B. The fund holds ACVA, citing its market share gains and strong fundamentals.

Intellia Therapeutics (NTLA) secured a $400 million debt facility from OrbiMed, with $75 million funded at closing and $225 million tied to milestones for lonvo-z, a CRISPR gene-editing therapy. The facility provides financial flexibility for lonvo-z's development and potential U.S. launch for hereditary angioedema (HAE). NTLA shares are up 0.63% at $12.76.